{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:09:34Z","timestamp":1794892174794,"version":"4.9.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shire, a Takeda company"},{"name":"Takeda Development Center Americas, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patient registries provide long-term, real-world evidence that aids the understanding of the natural history and progression of disease, and the effects of treatment on large patient populations with rare diseases. The year 2021 marks the 20th anniversary of the Fabry Outcome Survey (FOS), an international, multicenter, observational registry (NCT03289065). The primary aims of FOS are to broaden the understanding of Fabry disease (FD), an X-linked lysosomal storage disorder, and to improve the clinical management of affected patients. Here, we review the history of FOS and the analyses and publications disseminated from the registry, and we discuss the contributions FOS studies have made in understanding FD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>FOS was initiated in April 2001 and, as of January 2021, 4484 patients with a confirmed diagnosis and patient informed consent have been enrolled from 144 centers across 26 countries. Data from FOS have been published in nearly 60 manuscripts on a wide variety of topics relevant to FD. Analyses of FOS data have investigated the long-term effectiveness and safety of enzyme replacement therapy (ERT) with agalsidase alfa and its effects on morbidity and mortality, as well as the benefits of prompt and early treatment with agalsidase alfa on the progression of cardiomyopathy and the decline in renal function associated with FD. Based on analyses of FOS data, ERT with agalsidase alfa has also been shown to improve additional signs and symptoms of FD experienced by patients. FOS data analyses have provided a better understanding of the natural history of FD and the specific populations of women, children, and the elderly, and have provided practical tools for the study of FD. FOS has also provided methodology and criteria for assessing disease severity which contributed to the continuous development of medical practice in FD and has largely improved our understanding of the challenges and needs of long-term data collection in rare diseases, aiding in future rare disease real-world evidence studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>FOS over the last 20\u00a0years has substantially increased the scientific knowledge around improved patient management of FD and continues to expand our understanding of this rare disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02392-9","type":"journal-article","created":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T11:09:04Z","timestamp":1655723344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry"],"prefix":"10.1186","volume":"17","author":[{"given":"Michael","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4703-7447","authenticated-orcid":false,"given":"Uma","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hernberg-St\u00e5hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derralynn A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Pintos-Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Reisin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Anagnostopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaco","family":"Botha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giugliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,20]]},"reference":[{"issue":"2","key":"2392_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/gim.2015.42","volume":"18","author":"BK Potter","year":"2016","unstructured":"Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research? Genet Med. 2016;18(2):117\u201323.","journal-title":"Genet Med"},{"issue":"6","key":"2392_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jval.2011.05.002","volume":"14","author":"JT Clarke","year":"2011","unstructured":"Clarke JT, Giugliani R, Sunder-Plassmann G, Elliott PM, Pintos-Morell G, Hernberg-St\u00e5hl E, et al. FOS investigators. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS). Value Health. 2011;14(6):862\u20136.","journal-title":"Value Health"},{"key":"2392_CR3","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"E Hemberg-Stahl","year":"2006","unstructured":"Hemberg-Stahl E. Organization and technical aspects of FOS: the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006."},{"key":"2392_CR4","doi-asserted-by":"publisher","first-page":"232640981666629","DOI":"10.1177\/2326409816666298","volume":"4","author":"R Giugliani","year":"2016","unstructured":"Giugliani R, Niu D-M, Ramaswami U, West M, Hughes D, Kampmann C, et al. A 15-year perspective of the Fabry Outcome Survey. J Inborn Errors Metab Screen. 2016;4:2326409816666298. https:\/\/doi.org\/10.1177\/2326409816666298.","journal-title":"J Inborn Errors Metab Screen"},{"issue":"21","key":"2392_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry\u2019s disease Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163\u20137.","journal-title":"N Engl J Med"},{"key":"2392_CR6","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"A Mehta","year":"2006","unstructured":"Mehta A, Beck M, Linhart A, Sunder-Plassmann G, Widmer U. History of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006."},{"issue":"10","key":"2392_CR7","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/hmg\/3.10.1795","volume":"3","author":"CM Eng","year":"1994","unstructured":"Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet. 1994;3(10):1795\u20139.","journal-title":"Hum Mol Genet"},{"key":"2392_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/8904_2012_167","volume":"8","author":"W Terryn","year":"2013","unstructured":"Terryn W, Vanholder R, Hemelsoet D, Leroy BP, Van Biesen W, De Schoenmakere G, et al. Questioning the pathogenic role of the GLA p.Ala143Thr \u201cmutation\u201d in Fabry disease: implications for screening studies and ERT. JIMD Rep. 2013;8:101\u20138.","journal-title":"JIMD Rep."},{"issue":"1","key":"2392_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/ijms18010119","volume":"18","author":"TR Hsu","year":"2017","unstructured":"Hsu TR, Chang FP, Chu TH, Sung SH, Bizjajeva S, Yu WC, et al. Correlations between endomyocardial biopsies and cardiac manifestations in Taiwanese patients with the Chinese hotspot IVS4+919G>A mutation: data from the Fabry Outcome Survey. Int J Mol Sci. 2017;18(1):119.","journal-title":"Int J Mol Sci"},{"key":"2392_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/8904_2015_418","volume":"22","author":"HC Liu","year":"2015","unstructured":"Liu HC, Perrin A, Hsu TR, Yang CF, Lin HY, Yu WC, et al. Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G>A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS). JIMD Rep. 2015;22:107\u201313.","journal-title":"JIMD Rep"},{"issue":"6","key":"2392_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00439-017-1779-6","volume":"136","author":"PD Stenson","year":"2017","unstructured":"Stenson PD, Mort M, Ball EV, Evans K, Hayden M, Heywood S, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet. 2017;136(6):665\u201377.","journal-title":"Hum Genet"},{"issue":"3","key":"2392_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236\u201342.","journal-title":"Eur J Clin Invest."},{"issue":"11","key":"2392_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001;38(11):769\u201375.","journal-title":"J Med Genet"},{"issue":"11","key":"2392_CR14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH. Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750\u201360.","journal-title":"J Med Genet"},{"issue":"1","key":"2392_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2392_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"5","key":"2392_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","volume":"2","author":"HY Lin","year":"2009","unstructured":"Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450\u20136.","journal-title":"Circ Cardiovasc Genet"},{"key":"2392_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/cge.14102","volume":"101","author":"DP Germain","year":"2021","unstructured":"Germain DP, Levade T, Hachulla E, Knebelmann B, Lacombe D, Seguin VL, et al. Challenging the traditional approach for interpreting genetic variants: Lessons from Fabry disease. Clin Genet. 2021;101:390\u2013402.","journal-title":"Clin Genet."},{"key":"2392_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100529","volume":"21","author":"M Beck","year":"2019","unstructured":"Beck M, Cox TM. Comment: why are females with Fabry disease affected? Mol Genet Metab Rep. 2019;21: 100529.","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"2392_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","volume":"124","author":"C Wanner","year":"2018","unstructured":"Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab. 2018;124(3):189\u2013203.","journal-title":"Mol Genet Metab"},{"key":"2392_CR21","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"R Schiffman","year":"2006","unstructured":"Schiffman R, Brady RO. Development of enzyme replacement therapy for Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006."},{"key":"2392_CR22","unstructured":"Shire Human Genetic Therapies. REPLAGAL (agalsidase alfa) 1 mg\/ml concentrate for solution for infusion. Prescribing information for Great Britain (England, Scotland, Wales), Northern Ireland & Republic of Ireland. 2001. https:\/\/www.takeda.com\/4ad84f\/siteassets\/en-gb\/home\/hcps\/pi\/replagal_pi.pdf. Accessed 20 January 2021."},{"key":"2392_CR23","unstructured":"Genzyme. FABRAZYME\u00ae (agalsidase beta) for injection, for intravenous use. Prescribing information. 2003. https:\/\/products.sanofi.us\/Fabrazyme\/Fabrazyme.pdf. Accessed 20 January 2021."},{"key":"2392_CR24","unstructured":"ISU Abxis. FABAGAL\u00ae (agalsidase beta for injection). Prescribing information. 2021. http:\/\/www.abxis.com\/assets\/nprd_info03_eng.pdf. Accessed 10 December 2021."},{"key":"2392_CR25","unstructured":"Amicus. GALAFOLD\u00ae(migalastat) capsules, for oral use. Prescribing information. 2018. https:\/\/www.amicusrx.com\/pi\/galafold.pdf. Accessed 20 January 2021."},{"issue":"9706","key":"2392_CR26","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, et al. Fabry Outcome Survey investigators Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet. 2009;374(9706):1986\u201396.","journal-title":"Lancet."},{"issue":"2\u20133","key":"2392_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2010.06.002","volume":"101","author":"DA Hughes","year":"2010","unstructured":"Hughes DA, Ramaswami U, Barba Romero M, Deegan P. FOS investigators: age adjusting severity scores for Anderson\u2013Fabry disease. Mol Genet Metab. 2010;101(2\u20133):219\u201327.","journal-title":"Mol Genet Metab."},{"issue":"4","key":"2392_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65(4):299\u2013307.","journal-title":"Clin Genet"},{"issue":"3","key":"2392_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1136\/jmedgenet-2011-100407","volume":"49","author":"DA Hughes","year":"2012","unstructured":"Hughes DA, Malmen\u00e4s M, Deegan PB, Elliott PM, Ginsberg L, Hajioff D, et al. FOS investigators. Fabry International Prognostic Index: a predictive severity score for Anderson\u2013Fabry disease. J Med Genet. 2012;49(3):212\u201320.","journal-title":"J Med Genet."},{"key":"2392_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1477-7525-10-116","volume":"10","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Stull DE, Parini R, Pintos-Morell G, Whybra C, Kalkum G, et al. FOS investigators. Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ). Health Qual Life Outcomes. 2012;10:116.","journal-title":"Health Qual Life Outcomes."},{"key":"2392_CR31","volume-title":"Fabry disease: perspectives from 5 years of FOS","author":"C Whybra","year":"2006","unstructured":"Whybra C, B\u00e4hner F, Baron K. Measurement of disease severity and progression in Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis; 2006."},{"issue":"1","key":"2392_CR32","doi-asserted-by":"publisher","first-page":"12914","DOI":"10.1111\/ijcp.12914","volume":"71","author":"R Reisin","year":"2017","unstructured":"Reisin R, Perrin A, Garc\u00eda-Pav\u00eda P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract. 2017;71(1):12914.","journal-title":"Int J Clin Pract"},{"issue":"447","key":"2392_CR33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/08035320510031045","volume":"94","author":"E Schaefer","year":"2005","unstructured":"Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005;94(447):87\u201392 (discussion 79).","journal-title":"Acta Paediatr Suppl."},{"issue":"4","key":"2392_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1651-2227.2010.02101.x","volume":"100","author":"U Ramaswami","year":"2011","unstructured":"Ramaswami U, Parini R, Kampmann C, Beck M. Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatr. 2011;100(4):605\u201311.","journal-title":"Acta Paediatr"},{"issue":"5","key":"2392_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1399-0004.2011.01671.x","volume":"81","author":"U Ramaswami","year":"2012","unstructured":"Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M. FOS investigators. Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet. 2012;81(5):485\u201390.","journal-title":"Clin Genet."},{"key":"2392_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymgmr.2015.02.002","volume":"3","author":"M Beck","year":"2015","unstructured":"Beck M, Hughes D, Kampmann C, Larroque S, Mehta A, Pintos-Morell G, et al. Fabry Outcome Survey Study Group. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry Outcome Survey analysis. Mol Genet Metab Rep. 2015;3:21\u20137.","journal-title":"Mol Genet Metab Rep."},{"key":"2392_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years\u2019 treatment. Orphanet J Rare Dis. 2015;10:125.","journal-title":"Orphanet J Rare Dis"},{"key":"2392_CR38","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.2147\/DDDT.S207856","volume":"13","author":"U Ramaswami","year":"2019","unstructured":"Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, et al. FOS Study Group. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis. Drug Des Devel Ther. 2019;13:3705\u201315.","journal-title":"Drug Des Devel Ther."},{"issue":"12","key":"2392_CR39","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.clinthera.2020.10.007","volume":"42","author":"S Feriozzi","year":"2020","unstructured":"Feriozzi S, Linhart A, Ramaswami U, Kalampoki V, Gurevich A, Hughes D. Fabry Outcome Survey Study Group. Effects of baseline left ventricular hypertrophy and decreased renal function on cardiovascular and renal outcomes in patients with Fabry disease treated with agalsidase alfa: a Fabry Outcome Survey study. Clin Ther. 2020;42(12):2321\u201330.","journal-title":"Clin Ther."},{"issue":"Suppl 1","key":"2392_CR40","first-page":"gfz106.FP14","volume":"34","author":"M Cybulla","year":"2019","unstructured":"Cybulla M, Nicholls K, Feriozzi S, Torras J, Vujkovac B, Gurevich A, et al. Renoprotective effect of agalsidase alfa in Fabry disease is independent of type of mutation: results of 12-year follow-up. Nephrol Dial Transplant. 2019;34(Suppl 1):gfz106.FP14.","journal-title":"Nephrol Dial Transplant."},{"issue":"3","key":"2392_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ymgme.2011.03.022","volume":"103","author":"DA Hughes","year":"2011","unstructured":"Hughes DA, Barba Romero M, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2013the Fabry Outcome Survey. Mol Genet Metab. 2011;103(3):207\u201314.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"2392_CR42","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.3390\/ijms17121965","volume":"17","author":"M\u00c1 Barba-Romero","year":"2016","unstructured":"Barba-Romero M\u00c1, Pintos-Morell G. Gender differences in the application of Spanish criteria for initiation of enzyme replacement therapy for Fabry disease in the Fabry Outcome Survey. Int J Mol Sci. 2016;17(12):1965.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2392_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13023-016-0473-4","volume":"11","author":"M Lenders","year":"2016","unstructured":"Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-K\u00fchl S, Sommer C, et al. Multicenter Female Fabry Study (MFFS): clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis. 2016;11(1):88.","journal-title":"Orphanet J Rare Dis"},{"key":"2392_CR44","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.2147\/DDDT.S313789","volume":"15","author":"D Hughes","year":"2021","unstructured":"Hughes D, Linhart A, Gurevich A, Kalampoki V, Jazukeviciene D, Feriozzi S, et al. FOS Study Group. Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry Outcome Survey analysis. Drug Des Devel Ther. 2021;15:3561\u201372.","journal-title":"Drug Des Devel Ther."},{"key":"2392_CR45","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2147\/DDDT.S249433","volume":"14","author":"R Parini","year":"2020","unstructured":"Parini R, Pintos-Morell G, Hennermann JB, Hsu TR, Karabul N, Kalampoki V, et al. FOS Study Group. Analysis of renal and cardiac outcomes in male participants in the Fabry Outcome Survey starting agalsidase alfa enzyme replacement therapy before and after 18 years of age. Drug Des Devel Ther. 2020;14:2149\u201358.","journal-title":"Drug Des Devel Ther."},{"issue":"10","key":"2392_CR46","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry Outcome Survey. Eur Heart J. 2007;28(10):1228\u201335.","journal-title":"Eur Heart J."},{"key":"2392_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymgmr.2017.10.008","volume":"14","author":"M Beck","year":"2018","unstructured":"Beck M, Hughes D, Kampmann C, Pintos-Morell G, Ramaswami U, West ML, et al. Long-term outcomes with agalsidase alfa enzyme replacement therapy: analysis using deconstructed composite events. Mol Genet Metab Rep. 2018;14:31\u20135.","journal-title":"Mol Genet Metab Rep"},{"issue":"8","key":"2392_CR48","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, et al. FOS Investigators Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey. J Med Genet. 2009;46(8):548\u201352.","journal-title":"J Med Genet."},{"issue":"10","key":"2392_CR49","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1212\/WNL.0000000000001333","volume":"84","author":"M Lenders","year":"2015","unstructured":"Lenders M, Karabul N, Duning T, Schmitz B, Schelleckes M, Mesters R, et al. Thromboembolic events in Fabry disease and the impact of factor V Leiden. Neurology. 2015;84(10):1009\u201316.","journal-title":"Neurology"},{"issue":"8","key":"2392_CR50","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.amjhyper.2006.01.011","volume":"19","author":"J Kleinert","year":"2006","unstructured":"Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens. 2006;19(8):782\u20137.","journal-title":"Am J Hypertens"},{"issue":"5","key":"2392_CR51","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","volume":"67","author":"J Kleinert","year":"2005","unstructured":"Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, et al. Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. Kidney Int. 2005;67(5):1955\u201360.","journal-title":"Kidney Int"},{"issue":"5","key":"2392_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000168482","volume":"29","author":"S Feriozzi","year":"2009","unstructured":"Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M. International Fabry Outcome Survey Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol. 2009;29(5):353\u201361.","journal-title":"Am J Nephrol."},{"issue":"1","key":"2392_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2215\/CJN.03130411","volume":"7","author":"S Feriozzi","year":"2012","unstructured":"Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M. FOS investigators. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol. 2012;7(1):60\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"7 Suppl","key":"2392_CR54","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.1016\/j.ekir.2019.05.597","volume":"4","author":"K Nicholls","year":"2019","unstructured":"Nicholls K, West M, Gurevich A, Botha J, Cybulla M. Renoprotective effect of agalsidase alfa: 12-year follow-up of Fabry patients. Kidney Int Rep. 2019;4(7 Suppl):S239.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"2392_CR55","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ymgme.2018.12.392","volume":"126","author":"M West","year":"2019","unstructured":"West M, Cybulla M, Nicholls K, Feriozzi S, Torras J, Vujkovac B, et al. Renoprotective effect of agalsidase alfa: 12\u2013year follow-up of male Fabry patients. Mol Genet Metab. 2019;126(2):S1.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2392_CR56","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","volume":"22","author":"M Cybulla","year":"2009","unstructured":"Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G. European FOS Investigators Group. Kidney transplantation in patients with Fabry disease. Transpl Int. 2009;22(4):475\u201381.","journal-title":"Transpl Int."},{"issue":"447","key":"2392_CR57","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/08035320510028076","volume":"94","author":"A Mehta","year":"2005","unstructured":"Mehta A, Ginsberg L. FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl. 2005;94(447):24\u20137 (discussion 9\u201310).","journal-title":"Acta Paediatr Suppl."},{"issue":"1","key":"2392_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-017-0810-9","volume":"17","author":"HJ Lee","year":"2017","unstructured":"Lee HJ, Hsu TR, Hung SC, Yu WC, Chu TH, Yang CF, et al. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation. BMC Neurol. 2017;17(1):25.","journal-title":"BMC Neurol"},{"issue":"1","key":"2392_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12886-016-0374-2","volume":"16","author":"G Kalkum","year":"2016","unstructured":"Kalkum G, Pitz S, Karabul N, Beck M, Pintos-Morell G, Parini R, et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol. 2016;16(1):202.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"2392_CR60","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry\u2019s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2392_CR61","doi-asserted-by":"publisher","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","volume":"10","author":"S Pitz","year":"2015","unstructured":"Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLOS ONE. 2015;10(3):e0120814.","journal-title":"PLOS ONE"},{"issue":"9","key":"2392_CR62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1365-2362.2006.01701.x","volume":"36","author":"D Hajioff","year":"2006","unstructured":"Hajioff D, Hegemann S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, et al. Agalsidase alfa and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest. 2006;36(9):663\u20137.","journal-title":"Eur J Clin Invest"},{"issue":"455","key":"2392_CR63","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1651-2227.2007.00216.x","volume":"96","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr. 2007;96(455):84\u20136.","journal-title":"Acta Paediatr"},{"issue":"12","key":"2392_CR64","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S. Fabry Outcome Survey European Investigators. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447\u201353.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2392_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu CH, Jansen T, Lidove O, Jaussaud R, Hughes DA, Pintos-Morell G, et al. FOS Investigators. Fabry disease and the skin: data from FOS, the Fabry Outcome Survey. Br J Dermatol. 2007;157(2):331\u20137.","journal-title":"Br J Dermatol."},{"issue":"9","key":"2392_CR66","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1742-1241.2006.01061.x","volume":"60","author":"O Lidove","year":"2006","unstructured":"Lidove O, Ramaswami U, Jaussaud R, Barbey F, Maisonobe T, Caillaud C, et al. FOS European Investigators. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract. 2006;60(9):1053\u20139.","journal-title":"Int J Clin Pract."},{"issue":"3","key":"2392_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, de Lorenzo AG, Mehta A, Beck M, Widmer U, Ricci R. FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005;42(3):247\u201352.","journal-title":"J Med Genet."},{"key":"2392_CR68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jimd.12313","volume":"44","author":"M Beck","year":"2021","unstructured":"Beck M, Ramaswami U, Hughes D, Kampmann C, Nicholls K, Niu D-M, et al. Fabry Outcome Survey (FOS): demographics and survival analysis from a 20-year patient registry of Fabry disease. J Inherited Metab Dis. 2021;44:253\u20134.","journal-title":"J Inherited Metab Dis"},{"issue":"1","key":"2392_CR69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, et al. FOS European Investigators. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006;95(1):86\u201392.","journal-title":"Acta Paediatr."},{"issue":"4","key":"2392_CR70","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. European FOS Investigators. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006;43(4):347\u201352.","journal-title":"J Med Genet."},{"issue":"2","key":"2392_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1399-0004.2009.01345.x","volume":"77","author":"MA Barba-Romero","year":"2010","unstructured":"Barba-Romero MA, Deegan P, Giugliani R, Hughes D. Does geographical location influence the phenotype of Fabry disease in women in Europe? Clin Genet. 2010;77(2):131\u201340.","journal-title":"Clin Genet"},{"issue":"2","key":"2392_CR72","first-page":"67","volume":"123","author":"D Hughes","year":"2018","unstructured":"Hughes D, Romero M-\u00c1B, Gurevich A, Engrand P, Giugliani R. Menarche, menopause, and pregnancy data in untreated females and females treated with agalsidase alfa in the Fabry Outcome Survey. Mol Genet Metab. 2018;123(2):67.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2392_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2016.05.009","volume":"118","author":"O Lidove","year":"2016","unstructured":"Lidove O, Barbey F, Niu DM, Brand E, Nicholls K, Bizjajeva S, et al. Fabry in the older patient: clinical consequences and possibilities for treatment. Mol Genet Metab. 2016;118(4):319\u201325.","journal-title":"Mol Genet Metab"},{"key":"2392_CR74","unstructured":"Nowak A, Gurevich A, Kalampoki V, Hughes D. Use of agalsidase alfa in the elderly: clinical outcomes from the Fabry Outcome Survey. In: 16th Annual WORLD Symposium; 10\u201313 February 2020; Orlando, FL, USA. Poster LB-27."},{"issue":"11","key":"2392_CR75","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","volume":"11","author":"S Waldek","year":"2009","unstructured":"Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11(11):790\u20136.","journal-title":"Genet Med"},{"issue":"1","key":"2392_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12947-019-0151-5","volume":"17","author":"W Serra","year":"2019","unstructured":"Serra W, Marziliano N. Role of cardiac imaging in Anderson\u2013Fabry cardiomyopathy. Cardiovasc Ultrasound. 2019;17(1):1.","journal-title":"Cardiovasc Ultrasound"},{"key":"2392_CR77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/8904_2012_165","volume":"8","author":"J Villalobos","year":"2013","unstructured":"Villalobos J, Politei JM, Martins AM, Cabrera G, Amartino H, Lemay R, et al. Fabry disease in latin america: data from the fabry registry. JIMD Rep. 2013;8:91\u20139.","journal-title":"JIMD Rep"},{"issue":"2","key":"2392_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.amjcard.2017.04.016","volume":"120","author":"HC Wilson","year":"2017","unstructured":"Wilson HC, Hopkin RJ, Madueme PC, Czosek RJ, Bailey LA, Taylor MD, et al. Arrhythmia and clinical cardiac findings in children with Anderson\u2013Fabry disease. Am J Cardiol. 2017;120(2):251\u20135.","journal-title":"Am J Cardiol"},{"issue":"5","key":"2392_CR79","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138.","journal-title":"J Med Genet"},{"issue":"1\u20132","key":"2392_CR80","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","volume":"119","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016;119(1\u20132):151\u20139.","journal-title":"Mol Genet Metab"},{"key":"2392_CR81","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. 2013;8:29.","journal-title":"Orphanet J Rare Dis"},{"key":"2392_CR82","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"2392_CR83","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transpl. 2012;27(3):1042\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"2392_CR84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, St\u00f6rk S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331\u201341.","journal-title":"J Intern Med"},{"issue":"39","key":"2392_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16390","volume":"16","author":"K Wyatt","year":"2012","unstructured":"Wyatt K, Henley W, Anderson L, Anderson R, Nikolaou V, Stein K, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess. 2012;16(39):1\u2013543.","journal-title":"Health Technol Assess"},{"issue":"5","key":"2392_CR86","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","volume":"83","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard LA. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432\u20138.","journal-title":"Clin Genet"},{"issue":"9","key":"2392_CR87","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","volume":"34","author":"CV Madsen","year":"2019","unstructured":"Madsen CV, Granqvist H, Petersen JH, Rasmussen AK, Lund AM, Oturai P, et al. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrol Dial Transplant. 2019;34(9):1525\u201333.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2392_CR88","doi-asserted-by":"publisher","first-page":"e0233460","DOI":"10.1371\/journal.pone.0233460","volume":"15","author":"W Mauhin","year":"2020","unstructured":"Mauhin W, Benveniste O, Amelin D, Montagner C, Lamari F, Caillaud C, et al. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PLOS ONE. 2020;15(5):e0233460.","journal-title":"PLOS ONE"},{"issue":"12","key":"2392_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225071","volume":"14","author":"PD Yazdanfard","year":"2019","unstructured":"Yazdanfard PD, Madsen CV, Nielsen LH, Rasmussen AK, Petersen JH, Seth A, et al. Significant hearing loss in Fabry disease: study of the Danish nationwide cohort prior to treatment. PLOS ONE. 2019;14(12): e0225071.","journal-title":"PLOS ONE"},{"key":"2392_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100841","volume":"31","author":"PDW Yazdanfard","year":"2022","unstructured":"Yazdanfard PDW, Effraimidis G, Madsen CV, Nielsen LH, Rasmussen AK, Petersen JH, et al. Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort. Mol Genet Metab Rep. 2022;31: 100841.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02392-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T03:06:09Z","timestamp":1668395169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02392-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,20]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2392"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02392-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,20]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FOS was approved by the ethics institutional review boards of participating centers. Further, this registry was compliant with relevant global and local regulations and best practices: Good Pharmacoepidemiological Practice, Good Research for Comparative Effectiveness principles, and the relevant principles of the International Conference on Harmonisation Good Clinical Practice guidelines were followed as appropriate for an observational registry, consistent with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient consent for publication was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB reports honoraria for speaking and\/or advisory boards from Sanofi Genzyme and Takeda. He is a member of the FOS Steering Committee.\nUR reports honoraria for speaking and\/or advisory boards from Amicus Therapeutics, Sanofi Genzyme, and Takeda, and research grants from Amicus Therapeutics and Takeda. She is a member of the FOS Steering Committee.\nEH-S reports no conflict of interest.\nDAH reports honoraria from Amicus Therapeutics, Freeline Therapeutics, Idorsia, Protalix, Sanofi Genzyme, and Takeda. She is a member of the FOS Steering Committee.\nCK reports honoraria for speaking and\/or advisory boards from Amicus, BioMarin, Gore, and Takeda. He is a member of the FOS Steering Committee.\nABM reports honoraria from Amicus Therapeutics, Avrobio, Freeline Therapeutics, Protalix, Sanofi Genzyme, and Takeda. He is a former member of the FOS Steering Committee and past chair of the FOS Steering Committee.\nKN reports honoraria from Amicus Therapeutics, Sanofi Genzyme, and Takeda. She is a member of the FOS Steering Committee.\nD-MN reports honoraria and speaker fees from Sanofi Genzyme and Takeda, and research grants from BioMarin, Sanofi Genzyme, and Takeda. He is a member of the FOS Steering Committee.\nGP-M reports honoraria from Alexion, Amicus, BioMarin, Sanofi Genzyme, and Takeda, and unrestricted grants from Sanofi Genzyme and Takeda to the Vall d\u2019Hebron Research Foundation for funding research on rare diseases. He is a member of the FOS Steering Committee.\nRR reports honoraria, speaker fees, and consulting fees from Amicus Therapeutics, CSL Behring, Gador, Sanofi Genzyme, Novartis, and Takeda. He is a member of the FOS Steering Committee.\nMLW reports grants, personal fees, and travel support from Amicus Therapeutics, Idorsia, Protalix, Sanofi Genzyme, and Takeda. He is a member of the FOS Steering Committee.\nJS is an employee of Takeda Pharmaceuticals International AG. and is a stockholder of Takeda Pharmaceuticals Company Limited.\nCA is an employee of Takeda Pharmaceuticals International AG and is a stockholder of Takeda Pharmaceuticals Company Limited.\nJB is an employee of Takeda Pharmaceuticals International AG and is a stockholder of Takeda Pharmaceuticals Company Limited.\nRG reports honoraria, consulting fees, speaker fees, research funding, and\/or travel reimbursement from Abeona, Allievex, Amicus Therapeutics, Avrobio, Azafaros, BioMarin, Chiesi, Denali Therapeutics, Idorsia, Inventiva, Janssen, JCR Pharmaceuticals, Lysogene, Novartis, Paradigm Biopharma, Passage Bio, Protalix, PTC Therapeutics, Regenxbio, Sanofi Genzyme, Sigilon, Sobi, Takeda, and Ultragenyx. He is a member and current chair of the FOS Steering Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}